Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 10/20 | 0.58 |
| ▸ | PDE7B | Q9NP56 | 5/20 | 0.58 |
| ▸ | PDE8A | O60658 | 3/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100389 | 1.00 | PDE7A (0.58) | PDE7APDE7BPDE8AS1PR1S1PR5 | |
| SCHEMBL100455 | 0.90 | PDE7A (0.63) | PDE7APDE7BPDE8AS1PR1S1PR5 | |
| SCHEMBL136525 | 0.90 | PDE7A (0.53) | PDE7APDE7BPDE8AS1PR1S1PR5 | |
| SCHEMBL30837851 | 0.90 | PDE7A (0.66) | PDE7APDE7BPDE8AS1PR1S1PR5 | |
| SCHEMBL101241 | 0.90 | PDE7A (0.66) | PDE7APDE7BPDE8AS1PR1S1PR5 | |
| SCHEMBL100290 | 0.90 | PDE7A (0.66) | PDE7APDE7BPDE8AS1PR1S1PR5 | |
| SCHEMBL101209 | 0.89 | PDE7A (0.59) | PDE7APDE7BPDE8AS1PR1S1PR5 | |
| SCHEMBL100505 | 0.89 | PDE7A (0.58) | PDE7APDE7BPDE8AS1PR1S1PR5 | |
| SCHEMBL100182 | 0.89 | PDE7A (0.56) | PDE7APDE7BPDE8AS1PR1S1PR5 | |
| SCHEMBL30837809 | 0.89 | PDE7A (0.58) | PDE7APDE7BPDE8AS1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | MITODICURE GMBH (DE) | 2026-03-05 | — | — | US | disclosed |
| EP-4572765-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024038089-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | PDE5A, PDE4C, PDE12 | PDE7A 5/4885PDE7B 14/4885PDE8A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.